Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

September 14, 2021

Study Completion Date

January 10, 2022

Conditions
Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma ResectablePancreatic Ductal AdenocarcinomaPancreas Metastases
Interventions
DRUG

Ascorbic Acid

combination therapy

DRUG

Paclitaxel protein-bound

combination therapy

DRUG

Cisplatin

combination therapy

DRUG

Gemcitabine

combination therapy

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Cancer Research UK

OTHER

collaborator

Lustgarten Foundation

OTHER

collaborator

Translational Genomics Research Institute

OTHER

collaborator

Princeton University

OTHER

collaborator

Salk Institute for Biological Studies

OTHER

collaborator

Cold Spring Harbor Laboratory

OTHER

collaborator

Barts Cancer Institute

OTHER

collaborator

University of Arizona

OTHER

collaborator

Imaging Endpoints

UNKNOWN

lead

HonorHealth Research Institute

OTHER